Irinotecan News and Research

RSS
Irinotecan hydrochloride is approved by the Food and Drug Administration (FDA) to be used with other drugs to treat colorectal cancer that has metastasized (spread to other parts of the body). It is also approved to treat metastatic colorectal cancer that has recurred (come back) or gotten worse after earlier chemotherapy. In addition to the uses that have been approved by the FDA, irinotecan hydrochloride is sometimes used to treat other types of cancer. Irinotecan hydrochloride is also being studied in the treatment of other types of cancer.
SIR-Spheres safe, effective for patients with colorectal cancer liver metastases who have failed chemotherapy

SIR-Spheres safe, effective for patients with colorectal cancer liver metastases who have failed chemotherapy

Amgen reports top-line results from Vectibix Phase 3 trial for head and neck cancer

Amgen reports top-line results from Vectibix Phase 3 trial for head and neck cancer

Array BioPharma fiscal 2010 revenue increases to $53.9 million

Array BioPharma fiscal 2010 revenue increases to $53.9 million

Regeneron second-quarter total revenues increase to $115.9 million

Regeneron second-quarter total revenues increase to $115.9 million

Data on activity of Nektar's NKTR-102 in gastrointestinal cancer presented at ESMO 12th World Congress

Data on activity of Nektar's NKTR-102 in gastrointestinal cancer presented at ESMO 12th World Congress

Combination of Biothera's Imprime PGG and Erbitux doubles response rate in colorectal cancer patients

Combination of Biothera's Imprime PGG and Erbitux doubles response rate in colorectal cancer patients

Survey: 66% of patients with metastatic colorectal cancer are now tested for KRAS

Survey: 66% of patients with metastatic colorectal cancer are now tested for KRAS

Ph II data of perifosine + capecitabine in metastatic CRC to be presented at gastrointestinal cancer congress

Ph II data of perifosine + capecitabine in metastatic CRC to be presented at gastrointestinal cancer congress

Nektar commences dosing in Phase 1 study of NKTR-102 in combination with 5-FU/leucovorin

Nektar commences dosing in Phase 1 study of NKTR-102 in combination with 5-FU/leucovorin

Celator announces expansion of research agreement with Cephalon

Celator announces expansion of research agreement with Cephalon

First patient dosed in AR-42 Phase I/IIa clinical study at OSUCCC-James in adult patients with blood cancer

First patient dosed in AR-42 Phase I/IIa clinical study at OSUCCC-James in adult patients with blood cancer

Immunomedics initiates dosing in milatuzumab-doxorubicin conjugate Phase I/II trial for relapsed multiple myeloma

Immunomedics initiates dosing in milatuzumab-doxorubicin conjugate Phase I/II trial for relapsed multiple myeloma

Celator presents new data on CPX-351 liposome injection at European Hematology Association congress

Celator presents new data on CPX-351 liposome injection at European Hematology Association congress

Aeterna Zentaris reports final results on clinical activity of perifosine for metastatic colorectal cancer

Aeterna Zentaris reports final results on clinical activity of perifosine for metastatic colorectal cancer

Antiemetic-regimen with fosaprepitant injection provides similar protection against CINV as oral EMEND

Antiemetic-regimen with fosaprepitant injection provides similar protection against CINV as oral EMEND

EMEND indication helps women prevent CINV

EMEND indication helps women prevent CINV

NCC receives $25,000 grant award from Hospira Foundation to support pharmaceutical relief program

NCC receives $25,000 grant award from Hospira Foundation to support pharmaceutical relief program

New data highlighting Pfizer's approach to cancer drug development to be presented at ASCO meeting

New data highlighting Pfizer's approach to cancer drug development to be presented at ASCO meeting

Oncolytics Biotech initiates Phase I study of REOLYSIN and FOLFIRI in colorectal cancer patients

Oncolytics Biotech initiates Phase I study of REOLYSIN and FOLFIRI in colorectal cancer patients

REGN reports net loss of $30.5M for first-quarter 2010

REGN reports net loss of $30.5M for first-quarter 2010